Back

Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma

Park, H.-R.; Kim, S. J.; Kozlov, N.; Tagore, S.; Wu, L.; Izar, B.; Kim, M.

2026-03-23 cancer biology
10.64898/2026.03.19.712709 bioRxiv
Show abstract

An immunosuppressive tumor microenvironment limits therapeutic efficacy and worsens prognosis in melanoma. Beyond T-cell abundance and function, effective tumor control also depends on whether T cells can access malignant cells within the tumor. Although emerging evidence supports that tumor vasculature facilitates immune evasion, the vascular mechanisms that govern intratumoral T-cell positioning remain poorly defined. Using RNA sequencing of endothelial cells isolated from tumor cores versus peripheries in a mouse melanoma model, we identified intercellular adhesion molecule 1 (ICAM-1) as a candidate regulator of T-cell localization. During tumor growth, T cells shifted from a balanced core-margin distribution to marked exclusion from the core, most prominently in T cell-inflamed tumors. This spatial redistribution --less evident in other immune subsets--coincided with high expression of lymphocyte function-associated antigen-1 (LFA-1) on T cells. In parallel, endothelial ICAM-1 became enriched at the tumor periphery, where vascular integrity was compromised, as evidenced by increased vascular leakage and reduced pericyte coverage. Functionally, ICAM-1 blockade restored intratumoral T-cell infiltration, enhanced effector activity, and significantly delayed the growth of immunogenic tumors. Moreover, ICAM-1 inhibition sensitized an immune-refractory tumor to anti-PD-1 checkpoint blockade. Together, these findings identify endothelial ICAM-1 as a vascular determinant of intratumoral T-cell positioning and highlight the ICAM-1/LFA-1 axis as a modifiable checkpoint to reverse T-cell retention at the tumor periphery, thereby enhancing antitumor immunity and immunotherapy efficacy.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 4%
21.8%
2
Cell Reports
1338 papers in training set
Top 2%
12.1%
3
Nature Cancer
35 papers in training set
Top 0.1%
6.2%
4
Developmental Cell
168 papers in training set
Top 4%
4.7%
5
Journal of Experimental Medicine
106 papers in training set
Top 0.6%
4.7%
6
Immunity
58 papers in training set
Top 1%
4.2%
50% of probability mass above
7
Cancer Research
116 papers in training set
Top 1%
3.5%
8
Nature Cell Biology
99 papers in training set
Top 2%
2.6%
9
Cancer Immunology Research
34 papers in training set
Top 0.2%
2.6%
10
Journal of Clinical Investigation
164 papers in training set
Top 2%
2.5%
11
eLife
5422 papers in training set
Top 34%
2.3%
12
Cancer Cell
38 papers in training set
Top 0.8%
2.0%
13
Oncogene
76 papers in training set
Top 0.9%
1.8%
14
Cancer Discovery
61 papers in training set
Top 1%
1.8%
15
Cell Reports Medicine
140 papers in training set
Top 3%
1.8%
16
JCI Insight
241 papers in training set
Top 3%
1.7%
17
Science
429 papers in training set
Top 15%
1.6%
18
Science Translational Medicine
111 papers in training set
Top 4%
1.3%
19
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 38%
1.2%
20
Nature
575 papers in training set
Top 14%
0.9%
21
Science Advances
1098 papers in training set
Top 27%
0.9%
22
Blood
67 papers in training set
Top 1%
0.9%
23
EMBO reports
136 papers in training set
Top 6%
0.8%
24
Molecular Cell
308 papers in training set
Top 10%
0.7%
25
Science Immunology
81 papers in training set
Top 2%
0.7%
26
Cell
370 papers in training set
Top 18%
0.7%
27
Nature Genetics
240 papers in training set
Top 9%
0.6%
28
Cell Stem Cell
57 papers in training set
Top 3%
0.6%
29
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.6%
30
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1%
0.6%